Torsdag 26 December | 23:09:02 Europe / Stockholm

Kalender

Tid*
2026-02-19 13:00 Bokslutskommuniké 2025
2025-11-19 07:00 Kvartalsrapport 2025-Q3
2025-08-20 07:00 Kvartalsrapport 2025-Q2
2025-05-21 07:00 Kvartalsrapport 2025-Q1
2025-05-20 N/A Årsstämma
2025-02-26 13:00 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-10 - Extra Bolagsstämma 2024
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-30 - Split BGBIO 100:1
2024-05-29 - Kvartalsrapport 2024-Q1
2024-05-24 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2024-05-23 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-22 - Kvartalsrapport 2023-Q1
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2023-02-16 - Bokslutskommuniké 2022
2022-11-15 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-24 - Kvartalsrapport 2022-Q1
2022-04-29 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2022-04-28 - Årsstämma
2022-02-16 - Bokslutskommuniké 2021
2022-01-06 - Extra Bolagsstämma 2022
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-19 - Kvartalsrapport 2021-Q1
2021-03-22 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2021-03-19 - Årsstämma
2021-02-10 - Bokslutskommuniké 2020
2020-12-09 - Extra Bolagsstämma 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-19 - Kvartalsrapport 2020-Q1
2020-03-17 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2020-03-16 - Årsstämma
2020-02-11 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-19 - Kvartalsrapport 2019-Q2
2019-05-08 - Kvartalsrapport 2019-Q1
2019-03-14 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2019-03-13 - Årsstämma
2019-02-19 - Bokslutskommuniké 2018
2018-11-13 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-15 - Kvartalsrapport 2018-Q1
2018-05-15 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2018-05-14 - Årsstämma
2018-03-09 - Extra Bolagsstämma 2018
2018-02-13 - Bokslutskommuniké 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-23 - Kvartalsrapport 2017-Q1
2017-03-23 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2017-03-22 - Årsstämma
2016-06-22 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2016-06-21 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning BGBIO 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
BerGenBio är ett norskt onkologibolag. Idag bedriver bolaget forskning och utveckling av hämmande läkemedel för behandling av aggressiva cancertyper. Bolaget har utvecklat ett flertal produkter vars sammansättning ämnar blockera proteinet AXL, ett protein positivt relaterat med spridning av cancercellerna. Bolaget grundades under 2007 och har sitt huvudkontor i Bergen, Norge.
2023-06-07 17:20:12
Bergen 7 June 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the "Company") on 30 May 2023, regarding the
commencement of the subscription period in the rights issue (the "Rights Issue")
and the receipt of subscription rights in the Rights Issue by certain primary
insiders and certain close associates of primary insiders of the Company.

As of this date, 7 June 2023, the Company has been informed that the following
primary insiders and close associates in the Company have exercised their
subscription rights, as set out below:

Anders Tullgren, Chairman of the Board of Directors of the Company, has on 5
June 2023, exercised 1,409,872 subscription rights in the Rights Issue,
entitling Anders Tullgren to be allocated 1,409,872 offer shares in the Rights
Issue at a price per offer share of NOK 0.10, subject to the Rights Issue being
completed.

Svev AS, a company closely associated to Sveinung Hole which is a member of the
Board of Directors of the Company, has on 6 June 2023 exercised 2,000,000
subscription rights in the Rights Issue, entitling Svev AS to be allocated
2,000,000 offer shares in the Rights Issue at a price per offer share of NOK
0.10, subject to the Rights Issue being completed.

As of this date, 7 June 2023, the Company has been informed that the following
primary insiders and close associates in the Company have sold subscription
rights, as set out below:

Sveinung Hole, member of the Board of Directors of the Company, has on 6 June
2023 sold 83,182 subscription rights of his total holding of 83,182 subscription
rights in the Rights Issue.

Svev AS, a company closely associated to Sveinung Hole which is a member of the
Board of Directors of the Company, has on 6 June 2023 sold 945,053 subscription
rights of its total holding of 2,945,053 subscription rights in the Rights
Issue.

Sarsia Seed AS, a company closely associated to Sveinung Hole which is a member
of the Board of Directors of the Company, has on 6 June 2023 sold 44,000,000
subscription rights of its total holding of 59,719,358 subscription rights in
the Rights Issue.

The following primary insiders and close associates in the Company have sold and
purchased shares in the Company, as set out below:

Sveinung Hole, member of the Board of Directors of the Company, has on 6 June
2023 sold 2,950 shares in the Company of his total holding of 2,950 shares in
the Company.

Svev AS, a company closely associated to Sveinung Hole who is a member of the
Board of Directors of the Company, has on 6 June 2023 purchased 2,950 shares in
the Company. In addition, Svev AS has on 6 June 2023 sold 107,394 shares in the
Company of its total holding of 107,394 shares in the Company.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.